References:
1. Diamond EL, Durham BH, Haroche J, et al. Diverse and Targetable
Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discov .
2016;6(2):154-165.
2. Durham BH, Diamond EL, Abdel-Wahab O. Histiocytic neoplasms in the
era of personalized genomic medicine. Curr Opin Hematol .
2016;23(4):416-425.
3. Ozkaya N, Dogan A, Abdel-Wahab O. Identification and Targeting of
Kinase Alterations in Histiocytic Neoplasms. Hematol Oncol Clin
North Am . 2017;31(4):705-719.
4. Chakraborty R, Burke TM, Hampton OA, et al. Alternative genetic
mechanisms of BRAF activation in Langerhans cell histiocytosis.Blood . 2016;128(21):2533-2537.
5. Zarnegar S, Durham BH, Khattar P, et al. Novel activating BRAF fusion
identifies a recurrent alternative mechanism for ERK activation in
pediatric Langerhans cell histiocytosis. Pediatr Blood Cancer .
2018;65(1).
6. Lee LH, Gasilina A, Roychoudhury J, et al. Real-time genomic
profiling of histiocytoses identifies early-kinase domain BRAF
alterations while improving treatment outcomes. JCI Insight .
2017;2(3):e89473.
7. Durham BH, Lopez Rodrigo E, Picarsic J, et al. Activating mutations
in CSF1R and additional receptor tyrosine kinases in histiocytic
neoplasms. Nat Med . 2019;25(12):1839-1842.
8. Emile JF, Abla O, Fraitag S, et al. Revised classification of
histiocytoses and neoplasms of the macrophage-dendritic cell lineages.Blood . 2016;127(22):2672-2681.
9. Sievert AJ, Lang SS, Boucher KL, et al. Paradoxical activation and
RAF inhibitor resistance of BRAF protein kinase fusions characterizing
pediatric astrocytomas. Proc Natl Acad Sci U S A .
2013;110(15):5957-5962.
10. Jain P, Fierst TM, Han HJ, et al. CRAF gene fusions in pediatric
low-grade gliomas define a distinct drug response based on dimerization
profiles. Oncogene . 2017;36(45):6348-6358.
11. Jain P, Silva A, Han HJ, et al. Overcoming resistance to
single-agent therapy for oncogenic BRAF gene fusions via combinatorial
targeting of MAPK and PI3K/mTOR signaling pathways. Oncotarget .
2017;8(49):84697-84713.
12. Cin H, Meyer C, Herr R, et al. Oncogenic FAM131B-BRAF fusion
resulting from 7q34 deletion comprises an alternative mechanism of MAPK
pathway activation in pilocytic astrocytoma. Acta Neuropathol .
2011;121(6):763-774.
13. Roth JJ, Santi M, Pollock AN, et al. Chromosome band 7q34 deletions
resulting in KIAA1549-BRAF and FAM131B-BRAF fusions in pediatric
low-grade Gliomas. Brain Pathol . 2015;25(2):182-192.
14. Zhang C, Spevak W, Zhang Y, et al. RAF inhibitors that evade
paradoxical MAPK pathway activation. Nature .
2015;526(7574):583-586.
15. Okimoto RA, Lin L, Olivas V, et al. Preclinical efficacy of a RAF
inhibitor that evades paradoxical MAPK pathway activation in protein
kinase BRAF-mutant lung cancer. Proc Natl Acad Sci U S A .
2016;113(47):13456-13461.
16. Peng SB, Henry JR, Kaufman MD, et al. Inhibition of RAF Isoforms and
Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF
Mutant Cancers. Cancer Cell . 2015;28(3):384-398.
17. Gilmartin AG, Bleam MR, Groy A, et al. GSK1120212 (JTP-74057) is an
inhibitor of MEK activity and activation with favorable pharmacokinetic
properties for sustained in vivo pathway inhibition. Clin Cancer
Res . 2011;17(5):989-1000.
18. Jacobsen E, Abla O, Visser J. Malignant Histiocytoses. In: Abla O,
Janka G, eds. Histiocytic Disorders. Cham: Springer International
Publishing; 2018:361-381.
19. Ceppi F, Abla O. Juvenile Xanthogranuloma and Related Non-LCH
Disorders. In: Abla O, Janka G, eds. Histiocytic Disorders. Cham:
Springer International Publishing; 2018:293-311.
20. Picarsic J, Jaffe R. Pathology of Histiocytic Disorders and
Neoplasms and Related Disorders. In: Abla O, Janka G, eds. Histiocytic
Disorders. Cham: Springer International Publishing; 2018:3-50.